Merle, P., Blanc, J., Phelip, J., Pelletier, G., Bronowicki, J., Touchefeu, Y., Pageaux, G., Gerolami, R., Habersetzer, F., Nguyen-Khac, E., Casadei-Gardini, A., Borbath, I., Tran, A., Wege, H., Saad, A. S., Colombo, M., Abergel, A., Richou, C., Waked, I., Yee, N. S., Molé, A., Attali, P., Le Boulicaut, J., Vasseur, B., & , (2019). doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial. Lancet gastroenterology and hepatology, 4, 454–465. http://access.bl.uk/ark:/81055/vdc_100084767978.0x000004